SIRT1 and neoplasm: In terms of SIRT1’s oncogenic role, inhibiting it can disrupt tumorigenesis; for instance, LITAF increases FOXO1 levels, leading to SIRT1 downregulation, which diminishes the stemness and malignant phenotype of tumor cells (Guan et al., 2023).